Grace K. Suh, MD
Clinical Associate of Medicine
Grace K. Suh, MD, is a medical oncologist who is dedicated to caring for patients with complex malignancies. Her mission is to provide cancer patients with evidence-based and state-of-the-art treatments while offering compassion and empathy to each patient and his/her family. With that goal in mind, she is focused on bringing the highest level of academic medicine to each individual that she treats, not only to improve their outcomes but also to preserve their quality of life. Her clinical practice encompasses a broad range of cancer patients, where she approaches each patient with a team of doctors to provide multidisciplinary care.
As an accomplished researcher, Dr. Suh has been a principle investigator on several translational research projects. She has collaborated with world-renown cancer researchers and has presented her work at national and international meetings. She has also authored a number of review articles and book chapters on molecular oncology. Her research has been funded through grants from the National Institutes of Health, American Society of Clinical Oncology and the American Association for Cancer Research.
The University of Chicago Medicine
Center for Advanced Medicine
Year Started Practice
Yale University School of Medicine, New Haven, CT
Hospital of the University of Pennsylvania
Yale-New Haven Hospital, New Haven, CT
MD Anderson Cancer Center, Houston
American Association for Cancer Research
Office Postal Address
Grace K. Suh, MD
Request an appointment online
Physicians, contact the cancer intake line at (773) 702-8222.
Read More About Dr. Suh
Dr. Suh's practice is based at the University of Chicago Medicine Comprehensive Cancer Center at Silver Cross Hospital.
Grace K. Suh, Bryan T. Hennessy, Roeland Verhaak, Ji-Yeon Yang, Gordon B. Mills, and Robert C. Bast, Jr. Chapter 54; Molecular Targets for Epithelial Cancer. Molecular Oncology, Causes of Cancer and Targets for Treatment, edited by Edward P. Gelmann, Charles L. Sawyers, Frank J. Rauscher, III. Cambridge University Press.
Suh GK, Younes A. Prognosis and outcomes of lymphocyte-predominant Hodgkin's lymphoma. Nat Clin Pract Oncol. 2008 Aug;5(8):493.
Suh GK, McLaughlin P, Romaguera JE, Hagemeister FB, Pro B, Khouri IF, Samaniego F, Rodriguez MA, Fayad LE, Feng L, Younes A. Long-term follow-up of paclitaxel and topotecan plus rituximab (TTR) for patients with relapsed and refractory B-cell non-Hodgkin's lymphoma. 10th International Conference on Malignant Lymphoma: Lugano, Switzerland, June, 2008 (abstr 217).
Suh GK. Book Review. Final Exam: A Surgeon’s Reflection on Mortality. J Palliat Med 2007 June;10(3): 815-819.
Suh GK, McLaughlin P, Romaguera JE, Hagemeister FB, Pro B, Khouri IF, Samaniego F, Rodriguez MA, Fayad LE, Feng L, Younes A. Long-term follow-up of paclitaxel and topotecan plus rituximab (TTR) for patients with relapsed and refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 26: 2008 (May 20 suppl; abstr 8599).
Suh, GK. Oral presentation. ARHI-induced autophagy is mediated through transcription factor FoxO3a and can be rescued by growth factors. American Society for Cancer Research Annual Meeting, Denver, CO, April 19, 2009.
Badgwell DB, Lu Z, Le K, Gao F, Yang M, Suh GK, Bao JJ, Das P, Andreeff M, Chen W, Yu Y, Ahmed AA, S-L Liao W, Bast RC Jr. The tumor-suppressor gene ARHI (DIRAS3) suppresses ovarian cancer cell migration through inhibition of the Stat3 and FAK/Rho signaling pathways. Oncogene. 2012 Jan 5;31(1):68-79.